Added to YB: 2025-01-22
Pitch date: 2024-12-04
ADAP [bullish]
Adaptimmune Therapeutics plc
-93.26%
current return
Author Info
No bio for this author
Company Info
Adaptimmune Therapeutics plc, a commercial-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom.
Market Cap
$13.9M
Pitch Price
$0.72
Price Target
2.50 (+5055%)
Dividend
N/A
EV/EBITDA
-0.28
P/E
-0.08
EV/Sales
0.56
Sector
Biotechnology
Category
special_situation
Adaptimmune Therapeutics plc - $ADAP
ADAP: FDA-approved Tecelra for sarcoma, lete-cel BLA 2025. $178M mkt cap, $30M EV. Non-natural selling pressure ending. $367M peak sales potential. Uza-cel in H&N w/ Galapagos. PRAME & CD70 in pipeline. Cash $186M, need $200M. 2x-4x peak rev = $2.04-$4.60/sh. Catalysts: ASH data, rev ramp, ATC expansion, lete-cel approval.
Read full article (11 min)